NCT04273737

Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy

Use of Amantadine in Treating Cognitive and Motor Impairments in Adolescents and Adults With Cerebral Palsy

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Columbia University · Academic / Other
• Sex: All
• Age: 12 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Cerebral palsy (CP) is a common childhood-onset disability associated with motor and cognitive impairments, however most research is focused on motor outcomes. The aim of this study is to determine the effects of Amantadine, a dopaminergic agonist, on cognitive function in adolescents and adults with CP.

Detailed description

CP is a heterogeneous condition due to injury to the developing brain. It is a condition that is often marked by both cognitive and motor disorders as well as increased prevalence of depression and anxiety. While most studies have focused on improving motor dysfunction, fewer have investigated cognitive impairments associated with CP. Dedicating a study to research the pharmacotherapeutic effect of Amantadine on cognitive function in adolescents and adults with cerebral palsy fills an important gap in development of a potential innovative treatment for cognitive deficits. The investigators hope to determine the effects of Amantadine on cognitive function in adolescents and adults with CP. The investigators will also evaluate secondary goals of improving gross and fine motor skills and mood.

Conditions

• Cerebral Palsy

Interventions

Type	Name	Description
DRUG	Amantadine Hydrochloride	6-week long daily regimen of amantadine, twice a day, while documenting perceived effects in a diary.

Timeline

• Start date: 2020-02-28
• Primary completion: 2022-02-22
• Completion: 2022-02-22
• First posted: 2020-02-18
• Last updated: 2022-05-31
• Results posted: 2022-05-31

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study